Companies › Shanghai Zhimeng Biopharma
1 active drug program in 3 registered trials: 3 Phase 2; Neurology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CB03-154 | – | Phase 2 | Focal Epilepsy; ALS (Amyotrophic Lateral Sclerosis) | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06612775 | CB03-154 | Phase 2 | Focal Epilepsy | Neurology | Sep 2027 |
| NCT07082192 | CB03-154 | Phase 2 | ALS (Amyotrophic Lateral Sclerosis) | Neurology | Sep 2027 |
| NCT07238868 | CB03-154 | Phase 2 | Focal Epilepsy | Neurology | Jan 2029 |
No annotated target.
–
Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.